Rapport final
Nanobody based targeted radionuclide therapy amplified with Cherenkov luminescence activated photodynamic therapy - Debie Pieterjan
The first phase of the project was the synthesis of the Chlorin E6-Glucose conjugate. After this was achieved, cell studies were performed to study the concentration dependent uptake of the conjugate in cancer cells.
To combine this with the radionuclide activated nanobody, first a biodistribution study had to be performed with the novel 90Y-labelled anti-HER2 compound. This demonstrated an expected biodistribution pattern and opened the way to the final phase of the project.
However, as a result of the COVID pandemic, the 90Y supplier no longer offered this radionuclide, and left no suitable alternative. This effectively ended progress on the project in the scope of the Willy Gepts funding.